FIRST AMENDMENT TO LEASEEvolus, Inc. • March 7th, 2024 • Pharmaceutical preparations
Company FiledMarch 7th, 2024 Industry
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 7th, 2024 Company Industry JurisdictionTHIS STOCK PURCHASE AGREEMENT (this “ Agreement” ) is made and entered into as of September 30, 2014, between STRATHSPEY CROWN HOLDINGS, LLC, a Delaware limited liability company (“ Seller” ) and ALPHAEON CORPORATION, a Delaware corporation (“ Purchaser” ).
FIRST AMENDMENTEvolus, Inc. • March 7th, 2024 • Pharmaceutical preparations
Company FiledMarch 7th, 2024 IndustryThis FIRST AMENDMENT (“First Amendment ”) is effective as of February 26, 2014 (“First Amendment Effective Date ”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG ”) and Evolus Inc. (“EVOLUS ”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013 (the “Original Agreement ”).
AMENDMENT TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 7th, 2024 Company Industry JurisdictionTHIS AMENDMENT TO STOCK, PURCHASE AGREEMENT (this “ Amendment”) is made and entered into as of September 30, 2014 (the “Effective Date”), by and between STRATHSPEY CROWN HOLDINGS, LLC, a Delaware limited liability company (“Seller”) and ALFHAEON CORPORATION, a Delaware corporation (“Purchaser”).
Contract, and Distribution Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations • England and Wales
Contract Type FiledMarch 7th, 2024 Company Industry JurisdictionCERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.
SECOND AMENDMENTEvolus, Inc. • March 7th, 2024 • Pharmaceutical preparations
Company FiledMarch 7th, 2024 IndustryThis SECOND AMENDMENT (“Second Amendment ”) is effective as of July 15, 2014 (“Second Amendment Effective Date ”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG ”) and Evolus Inc. (“EVOLUS ”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated on February 26, 2014 (the “Original Agreement ”).